PCM
KZR

Prelude Capital Management’s Kezar Life Sciences KZR Stock Holding History

Prelude Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,929
Closed -$333K – 1427
2025
Q4 		$333K Buy
+52,929
New +$309K 0.02% 736
2024
Q3 		– Sell
-1,855
Closed -$11.1K – 1425
2024
Q2 		$11.1K Sell
1,855
-8,225
-82% -$62.5K ﹤0.01% 1179
2024
Q1 		$90.9K Buy
+10,080
New +$91.8K ﹤0.01% 1210
2023
Q3 		– Sell
-3,620
Closed -$88.7K – 1252
2023
Q2 		$88.7K Buy
3,620
+1,987
+122% +$51.7K 0.01% 941
2023
Q1 		$51.1K Buy
+1,633
New +$94.5K ﹤0.01% 1004

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Prelude Capital Management's KZR Position: Q1 2026 in Review

Prelude Capital Management sold out of Kezar Life Sciences (KZR) in Q1 2026, closing a stake of 52,929 shares — an estimated $333K sold.

Prelude Capital Management first reported a position in KZR in Q1 2023 and held it in 5 quarters. The position peaked at $333K in Q4 2025. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Prelude Capital Management reported no remaining Kezar Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 52,929 Kezar Life Sciences shares in Q1 2026, an estimated $333K.
  • Prelude Capital Management first reported a position in Kezar Life Sciences in Q1 2023 and held it in 5 quarters.
  • Prelude Capital Management's Kezar Life Sciences position peaked at $333K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.